Eden Biodesign Presents at PepTalk Protein Bioprocessing Conference
News Jan 07, 2009
Eden Biodesign Limited will be exhibiting at PepTalk in San Diego from January 11th to 16th 2009. PepTalk is one of the largest conferences of its kind devoted to formulating biologics, bioprocessing, antibody and protein therapeutics and protein science and technology.
In addition to exhibiting at PepTalk in San Diego, Dr David Simpson, Process Development Manager at Eden Biodesign Ltd in Liverpool will be hosting an interactive session on Tuesday January 13th on monitoring bioprocesses using Near Infra Red Spectroscopy (NIRS) techniques.
In line with the FDA’s endorsement of process analytical technology (PAT), Dr Simpson’s discussion will focus on the versatility and utility of NIRS in biotherapeutic manufacturing and its applicability in the rapid development of both bespoke and platform systems.
Specific areas for discussion will concentrate on the Eden Biodesign approach to the application of NIRS for production campaigns, maximizing early phase development, applicability to the specific variant expression systems and its use in assessing product stability.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE